StockData
Petros Pharmaceuticals, Inc. logo

Petros Pharmaceuticals, Inc. (PTPI) stock

PTPIOTCPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026Score 5/30
$0.00+0.00 (+5.56%)

Close on Oct 19, 2026Market cap $135.07KP/E –Yield –

Petros Pharmaceuticals ebitda

EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.

Petros Pharmaceuticals's ebitda for the twelve months ending Dec 31, 2024 was -$1.80M. For fiscal 2024 it was -$1.80M. The highest annual figure on record is -$1.80M in fiscal 2024.

Annual ebitda

PeriodPeriod endValueChange
FY2024Dec 31, 2024-$1.80M–
FY2023Dec 31, 2023-$10.33M–
FY2022Dec 31, 2022-$14.32M–
FY2021Dec 31, 2021-$11.17M–
FY2020Dec 31, 2020-$10.62M–

Quarterly ebitda

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q4 FY2024Dec 31, 2024$78.54K–
Q3 FY2024Sep 30, 2024-$457.91K–
Q2 FY2024Jun 30, 2024-$631.27K–
Q1 FY2024Mar 31, 2024-$785.09K–
Q4 FY2023Dec 31, 2023-$4.24M–
Q3 FY2023Sep 30, 2023-$3.98M–
Q2 FY2023Jun 30, 2023-$1.64M–
Q1 FY2023Mar 31, 2023-$482.50K-144.7%
Q4 FY2022Dec 31, 2022-$3.18M–
Q3 FY2022Sep 30, 2022-$12.11M–
Q2 FY2022Jun 30, 2022-$100.55K–
Q1 FY2022Mar 31, 2022$1.08M–
Q2 FY2021Jun 30, 2021-$2.55M–
Q1 FY2021Mar 31, 2021-$468.68K–
Q4 FY2020Dec 31, 2020-$2.64M–
Q3 FY2020Sep 30, 2020-$675.06K–
Q2 FY2020Jun 30, 2020-$3.36M–
Q1 FY2020Mar 31, 2020-$3.95M–

More Petros Pharmaceuticals figures

See a number that looks wrong?